ASTRAZENECA PHARMA INDIA LTD. - Astrazeneca Pharma India Limited Receives Import And Market Permission In Form CT-20 (Subsequent New Drug Approval) From The Drugs Controller General Of India For Dapagliflozin Tablets 10Mg
Download 
|
< Back |
| 06 Feb 2021 | |
| This is to inform that AstraZeneca Pharma India Limited has received Import and Market Permission in Form CT-20 (Subsequent New Drug Approval) from the Drugs Controller General of India for Dapagliflozin Tablets 10mg.<BR> <BR> Dapagliflozin Tablets 10mg is now approved for additional indication: For the treatment of patients of Chronic Kidney Disease up to Stage III (eGFR of greater than or equal to 30ml/min/1.73m2). <BR> <BR> The receipt of this permission paves way for the launch of Dapagliflozin Tablets 10mg into a new disease area to Nephrologists in India, subject to the receipt of related statutory approvals and licenses. | |
| View all announcements for ASTRAZENECA PHARMA INDIA LTD. | Source: BSE India |
© 2024 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback